Biosimulation for Accelerating Drug Development in Immuno-Oncology
| Piet van der Graaf, SVP Quantitative Science Services, Rik de Greef, Senior Vice President - Global Lead Quantitative Science Service iDD
A rapidly developing area within Complex Biologics is Immuno-Oncology(IO), where biosimulations have become integral in creating a path between clinical phases. This newly recognized method of cancer treatment can provide unique challenges in translational science, clinical development and navigating regulatory pathways. Certara will discuss how a disciplined and proven clinical pharmacology strategy, coupled with in silico modeling and simulation will maximize program efficiency and increase the likelihood of an IO program’s success.